Special Issues

The Effect of Nanoparticles and Natural Products on Health
Editor: Mohammed Abu El-Magd

Submission Deadline: 15 February 2024 (Status: Open)

Special Issue Editor

Prof. Mohammed Abu El-Magd      Email   |   Website
Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh, Egypt
Interests: nanotechnology; nanomedicine; stem cells; exosomes; biotechnology

Special Issue Information

Dear Colleagues,

During recent years it has been observed great advances in the field of nanotechnology, especially in the development of the nanoproducts (NPs) industry. The application of NPs alone or in combination with natural products in medicine have led to significant improvements on health therapies. NPs, especially natural nano-antimicrobials, have a potent antimicrobial effect that can improve health. Several NPs and natural products were also used to prevent and treat diseases. However, the full awareness of NPs effect on living organisms remains unclear. Due to their small size, NPs can be easily accumulated in various tissues causing oxidative damage to them. Thus, NPs could be toxic not only for microorganisms but also for humans and animals. Unlike NPs, most natural products have health-promoting effects with fewer or even no toxic effects. Therefore, using these natural products in form of NPs may have a dual benefit to health.

Mohammed Abu El-Magd
Guest Editor


nanoparticles; natural products; nutrition; nanotechnology; drug delivery

Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://www.biolifesas.org/journalx_brha/authorLogOn.action by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. Submitted manuscripts should be well formatted in good English.

Sort by Default Latest Most read  
Please wait a minute...
  • Select all
  • Article
    Chengcheng Li, Xiaoshuang Guo, Xinhang Dong, Hong Du, Xiaolei Jin
    Journal of Biological Regulators and Homeostatic Agents. 2023, 37(4): 2231-2242. https://doi.org/10.23812/j.biol.regul.homeost.agents.20233704.220
    Download PDF (41) HTML (0)   Knowledge map   Save

    Objective: Low-molecular-weight hyaluronic acid (LMW-HA) enhances osteoclast differentiation in vitro. However, whether LMW-HA promotes bone resorption in vivo remains unclear. This study aimed to identify the effect of LMW-HA on osteoclast formation and bone resorption in vivo and explore the underlying molecular mechanism.

    Methods: Phosphate-buffered saline (PBS), high-dose lipopolysaccharide (LPS), low-dose LPS, low-dose LPS + LMW-HA, and LMW-HA were subcutaneously administered into the calvariae in mice. Micro-computed tomography, tartrate-resistant acid phosphatase (TRAP) staining, and enzyme-linked immunosorbent assay (ELISA) for C-telopeptide of type I collagen (CTX-I) and TRAP-5b were conducted to analyze osteoclast formation and bone destruction. Serum levels of inflammatory cytokines were measured using ELISA. Real-time quantitative reverse transcription PCR (Polymerase Chain Reaction) was performed to evaluate cathepsin K (CTSK), matrix metallopeptidase 9 (MMP-9), TRAP, toll-like receptor-4 (TLR-4), interleukin-1β (IL-1β), tumor necrosis factor alpha (TNF-α), and interleukin-6 (IL-6) in peritoneal murine macrophages (PMMs), receptor activator of nuclear factor kappa-B (RANKL), and bone marrow stromal cells (BMSCs). Immunohistochemistry was used to evaluate the infiltration of F4/80 positive cells into the skin. Finally, we evaluated whether LMW-HA-enhanced osteoclast formation was inhibited by the TLR-4 inhibitor (Resatorvid, TAK-242).

    Results: Co-injection of LMW-HA and low-dose LPS significantly boosted skull destruction and increased the number of osteoclasts. The expression levels of osteoclast genes (TRAP, CTSK, MMP-9) expression, CTX-I, TRAP-5b, and inflammatory cytokines in the low-dose LPS + LMW-HA group were significantly higher than those in the low-dose LPS or LMW-HA groups (p < 0.01). Moreover, RANKL, TNF-α, IL-1β, IL-6, and TLR-4 mRNA expression and inflammatory cytokines (TNF-α, IL-1β, IL-6) levels in serum were significantly higher in the group administered with LPS + LMW-HA than those in the group administered low-dose LPS (p < 0.01). Furthermore, LMW-HA could promote infiltration of F4/80 positive cells into the skin and elevate TNF-α, IL-1β, and IL-6 mRNA expressions in PMMs and RANKL mRNA expression in BMSCs. TAK-242 reduced osteoclast formation enhanced by LMW-HA in vivo.

    Conclusions: Our findings indicate that LMW-HA increases the secretion of inflammatory cytokines and exacerbates LPS-induced osteolysis in vivo. However, further studies are required to elucidate this potential mechanism.